Hematopoietic Stem Cell Transplant for Sickle Cell Disease
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II study of patients with sickle cell disease. It aims to find out if
people with sickle cell disease can be cured by changing their immune system before they have
blood stem cell transplants. Doctors will give patients a new drug (fludarabine) to see if
this drug changes patients immune system and reduces the patient's cells (host) from
rejecting donor cells (graft) after the patient gets a Hematopoietic (blood) stem cell
transplant.